To read an article from the print magazine online, please enter the web code below, which can be found in the magazine under the article.

https://www.getdigital.de - Gadgets und mehr für Computerfreaks



Social Media
Share this article

“Our core competence is the production of vials, both liquid and freeze-dried, as well as liquid ampoules of various formats, containing various products,” states Managing Director Michael Isele. Recipharm in Wasserburg currently boasts five filling lines for its four formats as well as three packaging lines. “When operating under full load we are able to fill about 40,000 to 130,000 vials and ampoules per day.”

This enormous capacity is owed to recent major investment in the company’s capacities; the production buildings were inaugurated as recently as May of this year. “We operate on a fully automatic level and have implemented a Dividella (Swiss producer) line which offers extensive possibilities in the field of aggregation and serialization.”

In all its productivity, it is its high flexibility and extraordinary expertise concerning the lyophylization process that makes up Recipharm’s particular strength. The company always has its customers in mind and ensures high-quality service. “We always aim for longterm partnerships with our customers,” Mr. Isele emphasizes.

At the Wasserburg facilities, Recipharm works exclusively as a CMO (Contract Manufacturing Organization) without a distributive arm. “We deliver to customers worldwide, however we are not distributing directly into the market,” says the Managing Director. “Around 80% of our production goes abroad, 20% is produced for German customers.”

While Recipharm in Wasserburg operates as an independent company, its parent company is Swedish company Recipharm AB. “Our Swedish holding company was founded in 1995 through a management buy-out and has since experienced organic growth as well as expansion through acquisitions,” explains Mr. Isele. “It was within the latter process that the location in Wasserburg was acquired in 2010.” Since then, the Wasserburg facility also operates under the name Recipharm.

Globally, Recipharm is active at about 20 locations in ten different countries including its home country Sweden, as well as Italy, Spain, France, Portugal, the UK and the US. Latest additions are subsidiaries in India and in Israel. “Within the Recipharm group we have various locations with R&D facilities,” says Mr. Isele. “Here in Wasserburg we have a technological development site as well as a laboratory.”

Currently, 390 of the total 5,000 Recipharm staff are employed in Wasserburg. “Finding qualified staff isn’t always easy – the food sector is a major competitor in this respect,” admits the Managing Director, who says he enjoys guiding sites and employees in their development and working on international networks. “We cooperate with universities and the IHK (Chamber of Industry and Commerce), and I believe it is necessary to increase attraction through improved infrastructure.”

Michael Isele
We take part in various symposia and are represented at the CPHI in Madrid, the largest pharma convention in the world. Michael IseleManaging Director

In order to achieve this, Recipharm in Wasserburg makes an effort to cooperate with local politics. “Our future prospects are very positive,” emphasizes Mr. Isele. “With new projects lining up, we are a factor of stability for the region.”

About the Recipharm Group 

Recipharm is a leading contract development and manufacturing organisation (CDMO) in the pharmaceutical industry employing some 5,000 employees. The company offers manufacturing services for pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development.

Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 5.0 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.